Table 1 Recent randomized phase III trials studying accelerated partial breast irradiation in breast cancer
From: Current controversies in radiotherapy for breast cancer
ELIOT [18] | GEC-ESTRO [14] | Livi et al. [21] | ||||||
|---|---|---|---|---|---|---|---|---|
Technique | kV-IORT (INTRABEAM) | IOERT | Interstitial multicatheter brachytherapy | Intensity-modulated radiotherapy | ||||
Fractionation | 40–56 Gy WBI + 10–16 Gy boost | 1 × 20 Gy (+ EBRT in 15.2% of patients) | 50 Gy WBI + 10 Gy Boost | 1 × 21 Gy | 50 Gy WBI + 10 Gy Boost | - 8 × 4 Gy in 4 days (HDR) - 7 × 4.3 Gy in 4 days (HDR) - 50 Gy in 3–4 days (PDR) | 50 Gy WBI + 10 Gy Boost | 6 × 5 Gy in 2 weeks |
Inclusion criteria | Unifocal IDC, ≥ 45 years | 48–75 years, tumor size ≤ 2.5 cm | DCIS or pT1-2a (<3 cm) pN0/mi, margins ≥ 2 mm (≥5 mm for DCIS and ILC), no lymph-/hemangiosis, ≥ 40 years | Unifocal, ≤ 2.5 cm, > 40 years | ||||
Number of patients | 3451 | 1305 | 1184 | 520 | ||||
Recruitment period | 2000–2012 | 2000–2007 | 2004–2009 | 2005–2013 | ||||
Median follow up | 2.4 years | 5.8 years | 6.6 years | 5 years | ||||
Local recurrence at 5 years | 1.3% | 3.3% | 0.4% | 4.4% | 0.9% | 1.4% | 1.4% | 1.5% |
p = 0.042 (n.s.) HR n.a. | p = 0.0001 HR 9.3 (95% CI 3.3–26.3) | p = 0.42 HR n.a. | p = 0.86 HR 1.16 (95% CI 0.2–5.8) | |||||
Overall survival at 5 years | 94.7% | 95.1% | 96.8% | 96.9% | 95.6% | 97.3% | 96.6% | 99.4% |
p = 0.099 HR n.a. | p = 0.59 HR 1.1 (95% CI 0.7–1.9) | p = 0.11 HR n.a. | p = 0.057 HR 0.17 (95% CI 0.02–1.36) | |||||